Cipher Pharmaceuticals Renews Share Buyback Amid Record Financial Performance

MISSISSAUGA, ON – May 01, 2026 – Hot on the heels of a record-breaking fiscal year, Cipher Pharmaceuticals Inc. (TSX: CPH) has announced its intention to launch a new share repurchase program, signaling a significant vote of confidence from management in the company's valuation.

The specialty pharmaceutical firm confirmed that the Toronto Stock Exchange (TSX) has approved its new normal course issuer bid (NCIB), which is set to commence on May 5, 2026. Under the plan, Cipher is authorized to repurchase up to 1,490,343 of its common shares for cancellation over the next 12 months. This figure represents 10% of the company's public float, a substantial commitment aimed at enhancing shareholder value.

This move is not just a standard financial maneuver; it is a strategic declaration. By committing capital to buy its own stock, Cipher's leadership is effectively telling the market that they believe the shares are trading for less than their intrinsic worth. The announcement comes as the company rides a wave of formidable financial strength, making the buyback a potent symbol of its current position and future outlook.

A Strategy Backed by Strong Financials

The decision to initiate another NCIB is underpinned by an exceptionally strong performance in 2025. Cipher reported record-setting financial results, including a 51% surge in total revenue to $50.5 million and a staggering 137% increase in net income, which reached $27.3 million. This profitability translated directly into robust cash flow, with the company generating $29.7 million from operations over the year.

Crucially, Cipher has also been diligent in strengthening its balance sheet. The company made $35.0 million in debt repayments during 2025, slashing its outstanding debt from $40.0 million to just $5.0 million by year-end. This aggressive deleveraging provides significant financial flexibility and reduces risk, positioning the company to allocate capital more freely.

In its official announcement, Cipher stated its belief that, "from time to time, the Common Shares trade in price ranges that do not fully reflect their value." In these instances, the company considers acquiring its own shares for cancellation to be an "attractive and desirable use of its available funds." With ample cash flow and a fortified balance sheet, Cipher is well-equipped to act on this belief without compromising its operational stability.

The Buyback Blueprint and Past Performance

The new NCIB follows a similar program that is concluding on May 4, 2026. Under that previous bid, Cipher was approved to buy back up to 1,485,260 shares. According to the company's latest disclosure, it repurchased and cancelled 532,940 common shares at an average price of approximately CDN$13.90 per share. While this represents a significant investment of over $7.4 million, it also indicates that the company utilized only about 36% of its previous authorization, suggesting a disciplined approach to repurchasing shares only when market conditions were deemed most favorable.

For the upcoming NCIB, purchases will be made on the open market through the TSX and other Canadian trading systems at the prevailing market price. To comply with TSX rules, daily repurchases are capped at 7,505 shares, which is 25% of the average daily trading volume over the last six months. However, Cipher has explicitly stated its intention to utilize a provision that allows for one larger weekly block purchase, signaling a potentially more aggressive execution of the new program should the right price points emerge.

Balancing Shareholder Returns with Long-Term Growth

For any company in the specialty pharmaceutical sector, capital allocation is a critical balancing act. Funds can be directed toward internal research and development, strategic acquisitions to bolster product pipelines, or returned to shareholders through dividends and buybacks. Cipher's strategy appears to be a multi-pronged approach.

The significant debt reduction and the remaining $60.0 million available under its debt facility—plus a $25.0 million accordion option—indicate that the company has preserved substantial firepower for potential acquisitions. Management has previously highlighted a focus on seeking "accretive acquisitions of companies with strategic value." Therefore, the share buyback should not be viewed in isolation but as one component of a broader capital allocation strategy. It suggests that while management is actively hunting for growth opportunities, it also sees a compelling, low-risk return in investing in its own undervalued equity.

This dual-track strategy allows Cipher to reward current shareholders in the short-to-medium term by reducing the number of outstanding shares—which can boost earnings per share (EPS)—while simultaneously maintaining the capacity to fund the long-term growth drivers essential in the pharmaceutical industry.

Market Outlook and Investor Implications

Investors have reacted positively to Cipher's performance over the past year, with its stock price (CPH.TO) trending upwards and trading between a 52-week low of $11.87 and a high of $19.63. The renewal of the NCIB is likely to provide a continued layer of support for the stock price.

Analyst coverage for the company remains relatively light, but the consensus one-year price target among a handful of analysts sits at approximately $19.61 CAD. This suggests that the professional investment community shares management's view that there is further upside from the stock's recent trading levels. The buyback program serves as a tangible action to help close this perceived gap between market price and fair value.

As the new NCIB gets underway, investors will be closely watching the frequency and volume of the repurchases. The execution of the program will serve as a real-time indicator of management's conviction in the stock's undervaluation at different price points, all while the company continues to pursue its strategic objectives for long-term growth in the dynamic pharmaceutical landscape.